About BRAF V600E

BRAF Mutations in Pediatric Glioma

The BRAF V600E mutation is common in pediatric LGG and typically has a poor prognosis^1,2

BRAF V600E–mutated LGG has distinct and more aggressive clinical characteristics compared to wild type, including increased risk of progression²

5-year progression-free survival after tumor resection²

BRAF Mutation Testing

Identifying the BRAF mutation status is crucial to treatment planning

Testing modalities used to identify BRAF V600E mutations:

	Next-generation sequencing (NGS): scalable DNA sequencing that is able to simultaneously analyze multiple genes^3,4
	Mutation-specific polymerase chain reaction (PCR): rapidly making copies of small segments of DNA⁵
	Mutation-specific real-time PCR (rtPCR): a more sensitive technique than traditional PCR where targeted DNA segments are amplified and quantified simultaneously^3-5
	Immunohistochemistry (IHC): detects tumor cells harboring a specific antigen by cytoplasmic staining of cells containing a mutation-specific monoclonal antibody⁶
	Other testing methods: Sanger sequencing, pyrosequencing^3,4

NEXT: Resources

References: 1. Nobre L, Zapotocky M, Ramaswamy V, et al. Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol. 2020;4:PO.19.00298. doi:10.1200/PO.19.00298 2. Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol. 2017;35(25):2934-2941. doi:10.1200/JCO.2016.71.8726 3. Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, Ghiorzo P. The current state of molecular testing in the BRAF-mutated melanoma landscape. Front Mol Biosci. 2020;30(7):113. doi:10.3389/fmolb.2020.00113 4. Supplement to: Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicenter, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53-64. doi:10.1016/S1470-2045(21)00578-7 5. National Center for Biotechnology Information. Polymerase chain reaction (PCR). Updated November 11, 2017. Accessed November 12, 2022. https://www.ncbi.nlm.nih.gov/probe/docs/techpcr 6. Ihle M, Fassunke J, König K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14(1):1-13. doi:10.1186/1471-2407-14-13

About BRAF V600E

IMPORTANT SAFETY INFORMATION

INDICATION